Mirati Therapeutics announced that Laurie Stelzer, CFO, will depart the company on September 8, 2023, to pursue an external opportunity. Aaron Ondrey, senior vice president, financial planning and analysis, Mirati Therapeutics, will assume the role of interim CFO. Stelzer will remain as a consultant to the company through October 2023. Ondrey joined Mirati as senior vice president, FP&A, in July of 2022, bringing over 20 years of experience in financial management, strategic planning, capital allocation and mergers and acquisitions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRTX:
- Ideaya Biosciences price target raised to $35 from $30 at Oppenheimer
- Penn downgraded, Roblox upgraded: Wall Street’s top analyst calls
- Mirati Therapeutics upgraded to Buy from Neutral at Citi
- Mirati Therapeutics: Cancer Discovery publishes results from MRTX1719 trial
- UPS downgraded, Eli Lilly upgraded: Wall Street’s top analyst calls